BCL2L11 and glioblastoma: These results were consistent with our previous findings in GBM, suggesting that HDAC inhibition potentiates MEKi-induced apoptosis across different types of TPM cancers and that this effect is driven by rescue of pro-apoptotic BIM and BMF protein levels.